AU2002308637B2 - Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 - Google Patents

Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 Download PDF

Info

Publication number
AU2002308637B2
AU2002308637B2 AU2002308637A AU2002308637A AU2002308637B2 AU 2002308637 B2 AU2002308637 B2 AU 2002308637B2 AU 2002308637 A AU2002308637 A AU 2002308637A AU 2002308637 A AU2002308637 A AU 2002308637A AU 2002308637 B2 AU2002308637 B2 AU 2002308637B2
Authority
AU
Australia
Prior art keywords
cell
cancer
antibody
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002308637A
Other languages
English (en)
Other versions
AU2002308637A1 (en
Inventor
Nam H. Dang
Chikao Morimoto
Stuart Schlossman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Texas System
Original Assignee
Dana Farber Cancer Institute Inc
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, University of Texas System, University of Texas at Austin filed Critical Dana Farber Cancer Institute Inc
Publication of AU2002308637A1 publication Critical patent/AU2002308637A1/en
Application granted granted Critical
Publication of AU2002308637B2 publication Critical patent/AU2002308637B2/en
Priority to AU2007209787A priority Critical patent/AU2007209787B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002308637A 2001-05-11 2002-05-08 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 Ceased AU2002308637B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007209787A AU2007209787B2 (en) 2001-05-11 2007-08-17 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29053101P 2001-05-11 2001-05-11
US60/290,531 2001-05-11
PCT/US2002/014462 WO2002092127A1 (en) 2001-05-11 2002-05-08 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007209787A Division AU2007209787B2 (en) 2001-05-11 2007-08-17 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26

Publications (2)

Publication Number Publication Date
AU2002308637A1 AU2002308637A1 (en) 2003-05-01
AU2002308637B2 true AU2002308637B2 (en) 2007-05-17

Family

ID=23116424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002308637A Ceased AU2002308637B2 (en) 2001-05-11 2002-05-08 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26

Country Status (8)

Country Link
US (2) US7198788B2 (enExample)
EP (1) EP1392361A4 (enExample)
JP (1) JP2004533449A (enExample)
KR (1) KR100863624B1 (enExample)
CN (2) CN101172158A (enExample)
AU (1) AU2002308637B2 (enExample)
CA (1) CA2446806A1 (enExample)
WO (1) WO2002092127A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344653A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) * 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
CA2479679A1 (en) * 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
JP5717937B2 (ja) * 2002-12-06 2015-05-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
WO2005016911A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
CA2597407C (en) 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
BRPI0613770A2 (pt) * 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anticorpos anti-cd26 e métodos de uso destes
AU2006278573A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
NZ595430A (en) 2005-08-24 2013-05-31 Immunogen Inc Process for preparing maytansinoid antibody conjugates
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
KR101334934B1 (ko) * 2006-12-27 2013-11-29 삼성디스플레이 주식회사 유기발광표시장치의 에이징 방법
CA2680368A1 (en) * 2007-03-14 2008-09-25 The University Of Tokyo A method of treating malignant mesothelioma
KR200450480Y1 (ko) * 2008-09-22 2010-10-07 대우조선해양 주식회사 앵글 취부장치
WO2010099918A1 (en) * 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
WO2010141566A1 (en) 2009-06-03 2010-12-09 Immunogen, Inc. Conjugation methods
US8321012B2 (en) * 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
CN102781316B (zh) * 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
JPWO2011118804A1 (ja) * 2010-03-26 2013-07-04 国立大学法人徳島大学 新規抗ｃｄ９８抗体とその用途
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
AU2013216863B2 (en) * 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
JP6348848B2 (ja) 2012-02-13 2018-06-27 ガミダ セル リミテッド 間葉系幹細胞の増殖
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
IN2015DN03202A (enExample) 2012-10-04 2015-10-02 Immunogen Inc
EP2767549A1 (en) 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
CN107417691B (zh) * 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
US9464092B2 (en) 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
CN103694352B (zh) * 2013-12-19 2015-12-09 江苏众红生物工程创药研究院有限公司 一种抗 cd26 抗体及其制备方法
CN103709251B (zh) * 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
TWI677505B (zh) * 2014-08-18 2019-11-21 瑞士商艾迪安納股份有限公司 抗ｃｄ２６抗體及其用途
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN107406463A (zh) 2014-12-04 2017-11-28 细胞基因公司 生物分子共轭物
WO2016112261A2 (en) * 2015-01-09 2016-07-14 Medimmune, Llc Assay to detect human dpp-4
SG11201802915WA (en) * 2015-09-11 2018-05-30 Ys Ac Co Ltd Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
WO2017189526A1 (en) * 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
AU2018392227B2 (en) * 2017-12-22 2025-05-01 Adienne S.A. Quantitative cellular method for determining the biological activity of an anti-CD26 ligand
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
CN109535255B (zh) * 2018-12-28 2020-10-27 江苏众红生物工程创药研究院有限公司 一种抗人cd26抗体及其在检测试剂盒中的应用
WO2020236890A1 (en) * 2019-05-20 2020-11-26 Mayo Foundation For Medical Education And Research Treating chronic liver disease
CA3155930A1 (en) * 2019-09-27 2021-04-01 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US11723926B2 (en) 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022220232A1 (ja) * 2021-04-12 2022-10-20 国立大学法人 東京大学 すい臓がん検出用蛍光プローブ
BR112023022312A2 (pt) 2021-05-13 2023-12-26 Adienne S A Métodos de tratamento de dermatomiosite
IL308373A (en) 2021-05-13 2024-01-01 Adienne S A Methods for treating graft versus host disease
CN116023491A (zh) * 2021-10-25 2023-04-28 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用
CN114878820A (zh) * 2022-05-30 2022-08-09 湛江中心人民医院 肺腺癌病理诊断标志物及其应用
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
CN117568477B (zh) * 2023-10-17 2024-11-19 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Dpp4作为nk/t细胞淋巴瘤肿瘤标志物的应用
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074299A2 (en) * 2000-04-01 2001-10-11 The Research Foundation Of State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120642A (en) * 1989-11-28 1992-06-09 Coulter Corporation Monoclonal antibody which distinguishes helper inducer and suppressor inducer cd4+ lymphocytes
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6951924B2 (en) * 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
AU2001269123A1 (en) * 2000-07-10 2002-01-21 Bayer Aktiengesellschaft Regulation of human dipeptidyl-peptidase iv-like enzyme
IL155245A0 (en) * 2000-10-12 2003-11-23 Ferring Bv Novel serine protease genes related to dppiv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074299A2 (en) * 2000-04-01 2001-10-11 The Research Foundation Of State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis

Also Published As

Publication number Publication date
KR20040029984A (ko) 2004-04-08
US20030031665A1 (en) 2003-02-13
US7198788B2 (en) 2007-04-03
US7658923B2 (en) 2010-02-09
KR100863624B1 (ko) 2008-10-15
EP1392361A4 (en) 2009-08-05
EP1392361A1 (en) 2004-03-03
CN100341572C (zh) 2007-10-10
CN1671415A (zh) 2005-09-21
WO2002092127A1 (en) 2002-11-21
CA2446806A1 (en) 2002-11-21
JP2004533449A (ja) 2004-11-04
US20070207143A1 (en) 2007-09-06
CN101172158A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
AU2002308637B2 (en) Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
AU2002308637A1 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
Li et al. Characterization of SGN-CD123A, a potent CD123-directed antibody–drug conjugate for acute myeloid leukemia
ES2668874T3 (es) Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
US8658168B2 (en) Compositions and methods for homoconjugates of antibodies which induce growth arrest of apoptosis of tumor cells
ES2350477T5 (es) Internalización de anticuerpos anti-CD74 y métodos de uso
ES2341625T3 (es) Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas.
JPH09509053A (ja) Ｔ−細胞抗原、並びにｔ−細胞介在状態の診断及び処理へのそれらの使用
US20050281813A1 (en) Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
CN116672445A (zh) 连接蛋白(Cx)43半通道结合抗体及其用途
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
CN106573976B (zh) 抗cd84抗体、包含所述抗体的组合物及其用途
WO2003047623A1 (en) Treatment of prostate cancer by inhibitors of ncam2
CN101622342B (zh) 减轻癌性疾病的抗体
EP1487487A2 (en) Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
CN117561277A (zh) 治疗克隆性t细胞扩增的方法和材料
WO1998020896A1 (en) A method for inducing apoptosis of primary central nervous system b cell lymphomas
AU2007209787B2 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
US20040005317A1 (en) Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
WO2024255692A1 (zh) 人表皮生长因子3的抗体、其制备方法及其应用
CA2290722A1 (en) Consensus peptide presenting entities
HK1120415A (en) Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
US20040109863A1 (en) Methods of therapy and diagnosis using targeting of cells that express Ly-9
Kumar et al. Targeting CD30 in Patients with Hodgkin Lymphoma
US20040109862A1 (en) Methods of therapy and diagnosis using targeting of cells that express Ly-9

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired